In a significant step to support those seeking to quit smoking, NHS England has announced the reintroduction of Varenicline, an improved stop-smoking medication available by prescription. With the potential to aid tens of thousands of individuals in England, this daily tablet is seen as a powerful tool, alongside other treatments like e-cigarettes, in helping people quit smoking.
The Return of Varenicline
Previously known by the brand name Champix, Varenicline was previously available on the NHS but was withdrawn due to certain impurities found in its formulation. Now, an updated version has been deemed safe and effective, offering new hope for smokers who want to quit. The pill is designed to reduce cravings and block nicotine’s effects on the brain, while also easing withdrawal symptoms such as irritability and sleep issues. According to NHS England, Varenicline, when combined with behavioral support, has shown to help one in four users quit smoking for at least six months.
How Varenicline Compares
NHS England considers Varenicline as effective as e-cigarettes and even more effective than other nicotine replacement therapies, such as gums and patches. Importantly, it’s a prescription-only medicine, meaning it won’t be available over the counter. Those interested will need to consult their GP or a local NHS stop smoking service.
E-Cigarettes: A Complementary Aid
While Varenicline is now recommended for those wanting to quit, e-cigarettes remain a recognized cessation tool and may be offered as part of a short-term starter kit in some local areas. Since e-cigarettes aren’t licensed as medicines, GPs can’t prescribe them unless there’s a specific local NHS scheme. However, many areas have set up such services as part of the wider effort to help smokers quit.
The Impact on Public Health
With about six million smokers across the UK, the return of Varenicline could make a significant public health impact. Research from University College London suggests that helping more people quit could prevent approximately 9,500 smoking-related deaths over the next five years. Additionally, the NHS spends around ÂŁ2.5 billion each year treating smoking-related illnesses. By supporting more smokers to quit, these costs could decrease significantly, freeing up resources for other healthcare needs.
Expert Views
Experts like Hazel Cheeseman, CEO of Action on Smoking and Health, and Professor Nick Hopkinson from Imperial College London are hopeful about the impact of Varenicline. Cheeseman highlights the need for accessible treatment and supportive services, emphasizing that a medication alone is not enough. Professor Hopkinson notes that the unavailability of Varenicline in recent years has been a “real problem” and encourages those who have struggled to quit previously to seek out this medication.
For smokers looking to quit, Varenicline combined with counseling could be the right solution. Smokers are encouraged to explore their options through NHS Smokefree and speak with healthcare providers about the available support, including this new prescription option, to maximize their chances of successfully quitting.